<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241890</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 11-3-111</org_study_id>
    <nct_id>NCT01241890</nct_id>
  </id_info>
  <brief_title>Prevention of CF Exacerbation in Childhood: PREVEC Study</brief_title>
  <acronym>PREVEC</acronym>
  <official_title>Prevention of CF Exacerbation in Childhood (PREVEC): Early Recognition of Inflammation by Non-invasive Biomarkers in Exhaled Breath (Condensate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NCFS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiesie Pharmaceuticals B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary exacerbations of CF are an important cause for the experienced disability of
      patients, respiratory symptoms, and decreases in lungfunction, which require antibiotic
      therapy at home or in the hospital. Therefore, prevention of exacerbations in CF is
      important. The aim of this study was to assess the predictive properties of inflammatory
      markers in exhaled breath for pulmonary exacerbations in children with CF. In addition the
      reliability of home monitor assessments of symptoms and lungfunction was investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Definition of an exacerbation according to Treggiari MM et al.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Children</condition>
  <condition>Exhaled Breath Condensate</condition>
  <condition>Non-invasive Inflammatory Markers</condition>
  <condition>Volatile Organic Compounds</condition>
  <condition>Home Monitoring</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Children with Cystic Fibrosis, care as usual</arm_group_label>
    <description>Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Children with Cystic Fibrosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CF disease is defined as the combination of:

               1. characteristic clinical features (persistent pulmonary symptoms, meconium ileus,
                  failure to thrive, steatorrhoea);

               2. and/or abnormal sweat test (Chloride &gt; 60mM);

               3. and/or two CF mutations.

        Exclusion Criteria:

          1. cardiac abnormalities;

          2. mental retardation;

          3. no technical satisfactory performance of measurements;

          4. on the waiting list for lung transplantation;

          5. non-compliance with the home-assessments;

          6. patients with Burkholderia Cepacia;

          7. participation in another intervention trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Dompeling, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Children</keyword>
  <keyword>Exhaled Breath Condensate</keyword>
  <keyword>Non-invasive Inflammatory Markers</keyword>
  <keyword>Volatile Organic Compounds</keyword>
  <keyword>Home monitoring</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

